Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

INTRODUCTION: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. METHODS: We reviewed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Whitney E., Hong, Lingzhi, Mott, Frank E., Simon, George, Wu, Carol C., Rinsurongkawong, Waree, Lee, J. Jack, Lam, Vincent K., Heymach, John V., Zhang, Jianjun, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600084/
https://www.ncbi.nlm.nih.gov/pubmed/34820641
http://dx.doi.org/10.1016/j.jtocrr.2021.100237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600084/
https://www.ncbi.nlm.nih.gov/pubmed/34820641
http://dx.doi.org/10.1016/j.jtocrr.2021.100237

Ejemplares similares